These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26429220)

  • 21. Doctors and drug companies: the beauty and the beast?
    Guömundsson S
    Acta Ophthalmol Scand; 2005 Aug; 83(4):407-8. PubMed ID: 16029261
    [No Abstract]   [Full Text] [Related]  

  • 22. Ethics and the pharmaceutical industry.
    Green S
    Australas Psychiatry; 2008 Jun; 16(3):158-65. PubMed ID: 18568619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring Perceptions of Early-Career Psychiatrists About Their Relationships With the Pharmaceutical Industry.
    Stark TJ; Brownell AK; Brager NP; Berg A; Balderston R; Lockyer JM
    Acad Psychiatry; 2016 Apr; 40(2):249-54. PubMed ID: 26296632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry.
    Pratt IS; Hughes CL; Slevin TJ
    Med J Aust; 2010 Mar; 192(5):294. PubMed ID: 20301814
    [No Abstract]   [Full Text] [Related]  

  • 25. The medical profession and the pharmaceutical industry: when will we open our eyes?
    Breen KJ
    Med J Aust; 2004 Apr; 180(8):409-10. PubMed ID: 15089732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conflict of interest in the physician interface with the biomedical industry.
    Minnigan H; Chisholm CD
    Emerg Med Clin North Am; 2006 Aug; 24(3):671-85. PubMed ID: 16877136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of staff and residents with pharmaceutical industry: a survey of psychiatric training program policies.
    Chakrabarti A; Fleisher WP; Staley D; Calhoun L
    Ann R Coll Physicians Surg Can; 2002 Dec; 35(8 Suppl.):541-6. PubMed ID: 15015500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethical issues in the relationships with industry: an ongoing challenge. New Guidelines open for public comment.
    Komesaroff PA
    J Paediatr Child Health; 2005 Nov; 41(11):558-60. PubMed ID: 16398836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Attitudes and behaviors of psychiatry residents and psychiatrists working in training institutes towards the relationship between the pharmaceutical industry and physicians].
    Gülöksüz S; Oral ET; Ulaş H
    Turk Psikiyatri Derg; 2009; 20(3):236-42. PubMed ID: 19757223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Industry relations with emergency medicine graduate medical education programs.
    Kowalenko T; Char D; Marco C; Asher S; Raja A; Farrell S; Sokolove PE;
    Acad Emerg Med; 2009 Oct; 16(10):1025-30. PubMed ID: 19799581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.
    Hodges B
    CMAJ; 1995 Sep; 153(5):553-9. PubMed ID: 7641153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions between pharmaceutical representatives and doctors in training. A thematic review.
    Zipkin DA; Steinman MA
    J Gen Intern Med; 2005 Aug; 20(8):777-86. PubMed ID: 16050893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Physicians and drug industry: attitudes and practice].
    Aasland OG; Førde R
    Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2603-6. PubMed ID: 15534631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians.
    Brett AS; Burr W; Moloo J
    Arch Intern Med; 2003 Oct; 163(18):2213-8. PubMed ID: 14557219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can the relationship between doctors and drug companies ever be a healthy one?
    D'Arcy E; Moynihan R
    PLoS Med; 2009 Jul; 6(7):e1000075. PubMed ID: 19621069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doctor, do you have a minute? The dilemma posed by physician interaction with the pharmaceutical industry.
    Quan SF
    J Clin Sleep Med; 2007 Jun; 3(4):345-6. PubMed ID: 17694720
    [No Abstract]   [Full Text] [Related]  

  • 37. Interactions between doctors and pharmaceutical sales representatives in a former communist country. The ethical issues.
    Makowska M
    Camb Q Healthc Ethics; 2014 Jul; 23(3):349-55. PubMed ID: 24865182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronological changes in Japanese physicians' attitude and behavior concerning relationships with pharmaceutical representatives: a qualitative study.
    Saito S; Mukohara K; Miyata Y
    PLoS One; 2014; 9(9):e106586. PubMed ID: 25238544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment: interactions between the medical profession and the pharmaceutical industry in Australia.
    Kerridge I
    Australas Psychiatry; 2008 Jun; 16(3):166-8. PubMed ID: 18568620
    [No Abstract]   [Full Text] [Related]  

  • 40. What do Libyan doctors perceive as the benefits, ethical issues and influences of their interactions with pharmaceutical company representatives?
    Alssageer MA; Kowalski SR
    Pan Afr Med J; 2013; 14():132. PubMed ID: 23734277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.